2017
Novel insights into mesothelioma biology and implications for therapy
Abstract: Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alte…
Search citation statements
Paper Sections
Select...
176
140
44
11
Citation Types
5
330
0
7
Year Published
2018
2026
Publication Types
Select...
292
18
18
13
Relationship
11
330
Authors
Journals
Cited by 334 publications
(342 citation statements)
References 158 publications
5
330
0
7
“…Again, Trp53 loss was not causative, but likely potentiated the effusionâpromoting effects of KRAS , which we recently identified in metastatic effusions (Agalioti et al , 2017). Taken together with published work, our findings functionally validate the role of TP53 mutations in human MPM in driving biphasic histology, tumor progression and metastasis, and poor survival (Bueno et al , 2016; Yap et al , 2017). Hence, TP53âtargeted therapies may be prioritized for biphasic MPM when available (Brown et al , 2009).…”
Section: Discussionsupporting
confidence: 86%
“…Again, Trp53 loss was not causative, but likely potentiated the effusionâpromoting effects of KRAS , which we recently identified in metastatic effusions (Agalioti et al , 2017). Taken together with published work, our findings functionally validate the role of TP53 mutations in human MPM in driving biphasic histology, tumor progression and metastasis, and poor survival (Bueno et al , 2016; Yap et al , 2017). Hence, TP53âtargeted therapies may be prioritized for biphasic MPM when available (Brown et al , 2009).…”
Section: Discussionsupporting
confidence: 86%
“…This is in agreement with reduced VEGF levels in myeloma tumors treated with the heparanase inhibitor Roneparstat (SST0001) (14) and the involvement of heparanase in VEGF gene regulation (36). These results are important because they echo recent data showing that the addition of anti-VEGF monoclonal antibody (bevacizumab; Avastin) to pemetrexed and cisplatin chemotherapy improved survival, probably by targeting the tumor vasculature (24,37), which plays an important role in the progression of mesothelioma (38). Moreover, tumor cells were often detected in blood vessels of control mice but not in PG545treated tumor vessels or tumors developed in heparanase-KO mice.…”
Section: Discussionsupporting
confidence: 77%
“…In the latter, BAP1 inactivation occurs in ~60-80% and 70-85% of pleural and peritoneal MM, respectively, 27,28 while CDKN2A alterations are present in 50-100% of cases. 1 We corroborated the molecular differences in testicular cases with MTAP and BAP1 IHC, which, unlike pleural and peritoneal MM, showed infrequent loss of expression (17 and 22%, respectively). Overall, loss of MTAP or BAP1 expression occurred in non-overlapping tumours (i.e.…”
Section: Discussionsupporting
confidence: 73%
“…However, we found the frequency of alterations in CDKN2A (44%) and BAP1 (29%) to be lower in the testis than in mesotheliomas at other sites. In the latter, BAP1 inactivation occurs in ~60â80% and 70â85% of pleural and peritoneal MM, respectively, 27,28 while CDKN2A alterations are present in 50â100% of cases 1 . We corroborated the molecular differences in testicular cases with MTAP and BAP1 IHC, which, unlike pleural and peritoneal MM, showed infrequent loss of expression (17 and 22%, respectively).…”
Section: Discussionsupporting
confidence: 70%
